

Cenicriviroc Mesylate

Catalog No: tcsc0032631



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg



Specifications

CAS No:

497223-28-6

Formula:

$C_{42}H_{56}N_4O_7S_2$

Pathway:

Immunology/Inflammation;GPCR/G Protein;Anti-infection

Target:

CCR;CCR;HIV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 107.5 mg/mL (135.55 mM)

Alternative Names:

TAK-652 Mesylate;TBR-652 Mesylate

Observed Molecular Weight:

793.05


Product Description

Cenicriviroc is a dual **CCR2/CCR5** antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

IC50 & Target: CCR2/CCR5^[1]

In Vitro: Migration of mouse monocytes in response to carbon tetrachloride (CCL2) is reduced following pre-treatment with Ceniviroc Mesylate (CVC) at a concentration of 1 μ M. Compare to untreated and unstimulated cells, the average fold change in migrating cells (\pm SD) is 0.8 ± 0.2 ($p>0.05$) and 0.7 ± 0.4 ($p>0.05$) for CCL2-stimulated cells treated with Ceniviroc Mesylate and unstimulated cells treated with Ceniviroc Mesylate, respectively^[1]. Phenotypic susceptibility testing shows, for the four R5-tropic HIV-2 isolates, a median EC₅₀ for Ceniviroc Mesylate of 0.39 nM (0.03, 0.33, 0.45 and 0.98 nM). The dual-tropic and the X4-tropic HIV-2 strains are resistant to Ceniviroc Mesylate with EC₅₀ at >1000 nM, and Maximum percentages of inhibition (MPI) at 33% and 4%, respectively^[2].

In Vivo: Ceniviroc Mesylate (CVC) treatment leads to dose-related decrease in monocyte/macrophage recruitment, of similar or greater magnitude than those observed with dexamethasone (positive control), and achieving statistical significance at doses ≥ 20 mg/kg/day ($p[1]$).



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!